Original Article
Discontinuing Antiepileptic Drugs in Children with Epilepsy: A Comparison of a Six-Week and a Nine-Month Taper Period
N Engl J Med 1994; 330:1407-1410May 19, 1994
- Abstract
Background
The optimal regimen for discontinuing antiepileptic medications in children with epilepsy is unknown.
Methods
We randomly assigned 149 children to either a six-week or a nine-month period of drug tapering, after which therapy was discontinued. Each group was composed of patients who had been seizure-free for either two or four years before drug tapering was begun. Most patients were receiving one antiepileptic drug; none were taking more than two. The children were evaluated periodically during and after the taper period. Sixteen patients were lost to follow-up before the beginning of the taper period. Proportional-hazards regression analysis was used to assess the risk of seizure recurrence among the remaining 133 patients.
Results
Seizures recurred in 53 patients (40 percent). The mean duration of follow-up was 39 months (range, 11 to 105) for the patients who did not have a recurrence of seizures. Neither the length of the taper period (six weeks vs. nine months, P = 0.38) nor the length of time the patients were free of seizures before the taper period was begun (two years vs. four years, P = 0.20) significantly influenced the risk of seizure recurrence. The presence of mental retardation (relative risk, 3.1; 95 percent confidence interval, 1.5 to 6.2) or spikes in the electroencephalogram at the time of tapering (relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.4) increased the risk of seizure recurrence.
Conclusions
The risk of seizure recurrence during drug tapering and after the discontinuation of antiepileptic drug therapy in children with epilepsy is not different whether the medications are tapered over a six-week or a nine-month period.
Media in This Article
Figure 1
Proportion of Patients Remaining Seizure-free, According to the Length of the Taper Period.Figure 2
Proportion of Patients Remaining Seizure-free, According to the Length of Time They Were Seizure-free before the Taper Period Began.Article Activity
- Article
The increased awareness of the potentially adverse cognitive and behavioral effects of antiepileptic drugs and the social stigma implicit in their use have generated much interest in attempts to discontinue treatment in selected patients with epilepsy. In several studies of the tapering of antiepileptic drugs in children, adults, or both, the incidence of recurrent seizures when medications were tapered after a seizure-free interval of at least two years was less than 40 percent1-8. Although medications are traditionally tapered when the decision is made to stop treatment, the optimal regimen for withdrawal has received little attention. Recommendations for tapering antiepileptic drugs have ranged from abrupt discontinuation of therapy to gradual tapering over a period of two years1,3,5,6,8-16. In most recent studies, the taper period was three to six months,1-7,10-15 presumably reflecting the standard practice in epilepsy centers.
In this study we compared a six-week (relatively short) period and a nine-month (relatively long) period of drug tapering in a group of children with epilepsy who had had no seizures for either two or four years.
Methods
Design and Recruitment
The study design was prospective, randomized, and unblinded. The study protocol was approved by the review boards for the study of human subjects of the two participating medical schools, and informed consent was obtained for each child. All children receiving care at the pediatric epilepsy clinics at the two institutions who had had no seizures for approximately 18 months were eligible for the study. Patients who had had a single seizure or only febrile seizures were excluded, as were patients with neonatal seizures or infantile spasms, since the natural history of these conditions is unique.
The eligible children were randomly assigned by two coin tosses to have their dosage of antiepileptic medications tapered to zero over a period of six weeks or nine months after a seizure-free period of two or four years. A previously constructed table of the four possible combinations of heads and tails was then consulted. The result of the first toss determined the rate of tapering (six weeks or nine months), and the result of the second determined whether the period would begin after the patient had been seizure-free for two years or four years.
An electroencephalogram was obtained just before the start of the taper period. When the patient had reached the targeted seizure-free interval, the medications were tapered according to a standard scheme in which the taper period was divided into three equal parts (two weeks for the six-week group and three months for the nine-month group). The dose was reduced by 25 percent during each interval. The actual dose was as close to the calculated dose as was feasible with commercially available drug preparations. If the patient was receiving more than one drug, the drugs were tapered sequentially with the use of the same six-week or nine-month period for each. The dose of the barbiturates was tapered last.
In all analyses, follow-up was begun at the start of drug tapering, since that was the time at which the risk of seizure recurrence due to a reduction in the dose or the discontinuation of therapy began. Follow-up information during and after the taper period was obtained by telephone, at clinic visits, or both. All patients were followed for at least 11 months after the beginning of the taper period or until their seizures recurred.
The patients were considered to be compliant with the rate of drug tapering if the process was completed within two weeks of the specified target date for those in the six-week group or within four weeks in the nine-month group. To be in compliance with the timing of the start of the taper period, the patients had to begin the process within three months of their scheduled start date.
Seizures were classified according to the definitions of the International League against Epilepsy17 on the basis of history, electroencephalographic findings, and imaging criteria.
Statistical Analysis
A survival analysis of the data was performed with seizure recurrence as the hazard and the length of time to seizure recurrence (failure time) measured from the start of the taper period. Proportional-hazards regression analysis was used to compare the two taper groups (six weeks vs. nine months) and the two groups classified according to the length of time the patients were free of seizures before tapering was begun (two years vs. four years). Kaplan-Meier plots of the data were constructed. Differences in selected attributes between study groups were assessed with Pearson's chi-square test. All statistical tests were two-tailed.
A secondary, exploratory analysis of the effect of a number of additional factors, other than the rate of tapering or the duration of therapy before the taper period, on the risk of seizure recurrence was performed. Proportional-hazards analysis was also used to calculate the relative risks for these selected variables after adjustment for any differences in the rate or timing of drug tapering.
Results
Of the 150 children who were considered for the study, 1 declined to participate. The outcome of the 149 patients who initially entered the study is shown in Table 1Table 1
Outcome of Patients Entering the Study, According to the Length of the Taper Period.. Sixteen patients were lost to follow-up before the start of the taper period. The primary analysis was carried out on the 133 patients who remained in the study at the start of the taper period. The results of a secondary analysis of the 111 patients who correctly completed the taper protocol were similar. The mean duration of follow-up was 39 months for the 80 patients who did not have a recurrence of seizures (range, 11 to 105). Overall, seizures recurred in 53 patients (40 percent).Rate of Tapering
The number of patients who were lost to follow-up or had a recurrence of seizures before the beginning of the planned taper period was similar in the two taper groups (Table 1). More patients (or their parents) in the nine-month group than in the six-week group later decided not to proceed with the taper process.
The characteristics of the 133 patients who completed the protocol are shown in Table 2Table 2
Characteristics of the Children with Epilepsy in Whom Treatment Was Discontinued.. The mean duration of follow-up after the start of the taper period for patients who did not have a recurrence of seizures was slightly longer in the six-week group than the nine-month group (44 months [range, 11 to 105] vs. 33 months [range, 11 to 91], P = 0.07).Figure 1Figure 1
Proportion of Patients Remaining Seizure-free, According to the Length of the Taper Period. shows the proportion of patients remaining seizure-free after the start of either a six-week or a nine-month period of drug tapering. The curves were not significantly different (P = 0.38). Seizures eventually recurred in 30 of 70 patients (43 percent) who underwent six weeks of drug tapering and 23 of 63 patients (36 percent) who underwent nine months of drug tapering (P = 0.46 by the chi-square test).Duration of Seizure-free Period before the Start of the Taper Period
Compliance with the scheduled start of the taper period was less reliable. Ten of 72 patients who had been seizure-free for two years before drug tapering was begun (14 percent) and 25 of 61 patients who had been seizure-free for four years (41 percent) did not begin the taper period at the scheduled time (P<0.001). The most common deviations from the schedule were longer-than-expected treatment in the two-year group and shorter-than-expected treatment in the four-year group. Both groups were similar with respect to the characteristics listed in Table 2. The mean duration of follow-up for patients who did not have a recurrence of seizures during drug tapering was similar in the two-year and four-year groups (42 and 36 months, respectively; P = 0.24). Figure 2Figure 2
Proportion of Patients Remaining Seizure-free, According to the Length of Time They Were Seizure-free before the Taper Period Began. shows the proportion of patients remaining seizure-free after the start of the taper period in the two groups. There was a trend toward a greater risk of seizure recurrence in the group that had been seizure-free for two years before drug tapering was begun, although the curves were not significantly different (P = 0.20). Similarly, in a chi-square analysis, more patients in the two-year group than in the four-year group had a recurrence of seizures (34 of 72 patients [47 percent] vs. 19 of 61 patients [31 percent], P = 0.06).Risk Factors for Recurrence of Seizures
The relative risks of seizure recurrence for 12 variables on which information was available are shown in Table 3Table 3
Risk Factors for Seizure Recurrence in 133 Children with Epilepsy during and after Tapering of Antiepileptic Drugs.. The presence of mental retardation and the presence of spikes in the electroencephalogram obtained just before the start of the taper period increased the likelihood of a recurrence of seizures.Discussion
We found an overall risk of seizure recurrence (40 percent) similar to that in other studies of both adults and children in whom antiepileptic drugs were discontinued over periods ranging from 1 to 18 months1,3-6,10-15. The similar success rates reported in these studies indirectly support the contention that the duration of the taper period is not a major determinant of the risk of seizure recurrence, at least in the range of periods studied.
Although the abrupt discontinuation of antiepileptic drug therapy has been advocated,2 there is evidence to support the benefit of gradual tapering, especially in the case of barbiturates or benzodiazepines18-29. The type of medication being tapered did not affect the risk of seizure recurrence in our study, suggesting that six weeks is an adequate taper period, even for barbiturates.
The question of the optimal rate of tapering has rarely been directly addressed. In three nonrandomized studies,2,8,30 there was no correlation between the risk of seizure recurrence and the length of the taper period if abrupt discontinuation was excluded. In a randomized study of the discontinuation of antiepileptic drugs, the risk of seizure recurrence was increased if the drugs were discontinued over a period of less than six months31. Several aspects of that study may explain the discrepancy between their findings and our findings. First, the restrictive definition of epilepsy used in that study probably led to the selection of patients with more severe seizures. Second, multiple medications were stopped simultaneously rather than sequentially. Finally, the sizes of the treatment groups differed greatly, calling into question the effectiveness of the study's randomization process, so that unidentified confounding factors may explain the poorer outcome with the shorter taper periods.
Other studies have reached conflicting conclusions regarding the effect on the risk of seizure recurrence of the duration of the seizure-free period before drug tapering is initiated3,6,8. We found a trend toward a lower risk of seizure recurrence in the group that had been seizure-free for four years before drug tapering was begun, but the shorter follow-up after the start of the taper period in this group might have biased the study in their favor. On the other hand, the risk of recurrence in this group might have been even lower had more patients waited the prescribed four years before starting the taper period.
Some compromise, individually determined for each patient, must be reached between the possibly lower risk of seizure recurrence with a longer duration of treatment and the cumulative costs of longer treatment regimens before tapering is begun. These include financial, social, and psychological costs as well as the direct adverse effects of medication.
No general agreement has been reached on the factors that affect the risk of seizure recurrence when antiepileptic drugs are tapered1,3-8,11-13,31-35. In our study, only the presence of mental retardation or spikes on the electroencephalogram obtained just before the start of the taper period increased the risk of seizure recurrence.
There are several advantages to a shorter taper period. Medication expenses will be lower. The length of time during which a patient must be restricted from activities such as driving may be reduced. Likewise, the outcome of the attempt to discontinue treatment may be known sooner, shortening the period of adjustment for the patient.
On the basis of our findings of a similar risk of seizure recurrence with a six-week and a nine-month taper period, we recommend that antiepileptic medications be tapered over a period of six weeks when a decision is made to discontinue treatment of children with epilepsy.
Supported in part by grants from the General Clinical Research Center (RR 000046) and the National Institutes of Health (R01-DE-06541).
Source Information
From the Departments of Neurology (M. Tennison, R.G.) and Pediatrics (M. Tennison, R.G.) and the Curriculum in Neurobiology (R.G.), University of North Carolina at Chapel Hill; the Department of Pediatrics, Duke University, Durham, N.C. (D.L.); and Burroughs Wellcome Company, Research Triangle Park, N.C. (M. Thorn).
Address reprint requests to Dr. Tennison at CB# 7025, UNC-CH, Chapel Hill, NC 27599-7025.
- References
References
1
Arts WF ,Visser LH ,Loonen MC , et al. Follow-up of 146 children with epilepsy after withdrawal of antiepileptic therapy. Epilepsia 1988;29:244-250
CrossRef | Web of Science | Medline2
Juul-Jensen P . Frequency of recurrence after discontinuance of anticonvulsant therapy in patients with epileptic seizures. Epilepsia 1964;5:352-363
CrossRef | Web of Science | Medline3
Medical Research Council Antiepileptic Drug Withdrawal Study Group
Web of Science | Medline4
Matricardi M ,Brinciotti M ,Benedetti P . Outcome after discontinuation of antiepileptic drug therapy in children with epilepsy. Epilepsia 1989;30:582-589
CrossRef | Web of Science | Medline5
Bouma PA ,Peters AC ,Arts RJ ,Stijnen T ,Van Rossum J . Discontinuation of antiepileptic therapy: a prospective study in children. J Neurol Neurosurg Psychiatry 1987;50:1579-1583
CrossRef | Web of Science | Medline6
Shinnar S ,Vining EPG ,Mellits ED , et al. Discontinuing antiepileptic medication in children with epilepsy after two years without seizures: a prospective study. N Engl J Med 1985;313:976-980
Full Text | Web of Science | Medline7
Callaghan N ,Garrett A ,Goggin T . Withdrawal of anticonvulsant drugs in patients free of seizures for two years: a prospective study. N Engl J Med 1988;318:942-946
Full Text | Web of Science | Medline8
Mastropaolo C ,Tondi M ,Carboni F ,Manca S ,Zoroddu F . Prognosis after therapy discontinuation in children with epilepsy. Eur Neurol 1992;32:141-145
CrossRef | Web of Science | Medline9
Merritt HH . Medical treatment in epilepsy. BMJ 1958;1:666-669
CrossRef | Web of Science | Medline10
Zenker C ,Groh C ,Roth G . Probleme und Erfahrungen beim Absetzen antikonvulsiver Therapie. Neue Osterreichische Z Kinderheilkd 1957;2:152-163
Medline11
Holowach J ,Thurston DL ,O'Leary J . Prognosis in childhood epilepsy: follow-up study of 148 cases in which therapy had been suspended after prolonged anticonvulsant control. N Engl J Med 1972;286:169-174
Full Text | Web of Science | Medline12
Emerson R ,D'Souza BJ ,Vining EP ,Holden KR ,Mellits ED ,Freeman JM . Stopping medication in children with epilepsy: predictors of outcome. N Engl J Med 1981;304:1125-1129
Full Text | Web of Science | Medline13
Oller-Daurella L, Pamies R, Oller LFV. Reduction or discontinuance of antiepileptic drugs in patients seizure-free for more than 5 years. In: Janz D, ed. Epileptology: proceedings of the Seventh International Symposium on Epilepsy, Berlin (West), June 1975. Stuttgart, Germany: Georg Thieme Verlag, 1976:218-27.
14
Overweg J, Rowan AJ, Binnie CD, Oosting J, Nagelkerke NJD. Prediction of seizure recurrence after withdrawal of antiepileptic drugs. In: Dam M, Gram L, Penry JK, eds. Advances in epileptology: the XIIth Epilepsy International Symposium. New York: Raven Press, 1981:503-8.
15
Oller-Daurella L, Oller LF-V, Paimes R. Clinical, therapeutic, and social status of epileptic patients without seizures for more than five years. In: Penry JK, ed. Epilepsy: the eighth international symposium. New York: Raven Press, 1977:69-75.
16
Duncan JS ,Shorvon SD . Rates of antiepileptic drug reduction in active epilepsy -- current practice. Epilepsy Res 1987;1:357-364
CrossRef | Web of Science | Medline17
Commission on Classification and Terminology of the International League against Epilepsy
CrossRef | Web of Science | Medline18
Fox JT . Luminal-sodium in the treatment of epilepsy. Lancet 1927;2:589-592
CrossRef | Web of Science19
Grinker RR . The proper use of phenobarbital in the treatment of the epilepsies. JAMA 1929;93:1218-121920
Theodore WH ,Porter RJ ,Raubertas RF . Seizures during barbiturate withdrawal: relation to blood level. Ann Neurol 1987;22:644-647
CrossRef | Web of Science | Medline21
Theodore WH ,Porter RJ . Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy. Ann Neurol 1983;13:320-324
CrossRef | Web of Science | Medline22
Isbell H ,Altschul S ,Kornetsky CH ,Eisenman AJ ,Flanary HG ,Fraser HF . Chronic barbiturate intoxication: an experimental study. Arch Neurol Psychiatr 1950;64:1-28
Web of Science | Medline23
Wikler A ,Fraser HF ,Isbell H ,Pescor FT . Electroencephalograms during cycles of addiction to barbiturates in man. Electroencephalogr Clin Neurophysiol 1955;7:1-13
CrossRef | Medline24
Kalinowsky LB . Convulsions in nonepileptic patients on withdrawal of barbiturates, alcohol and other drugs. Arch Neurol Psychiatr 1942;48:946-956
Web of Science25
Wulff MH. The barbiturate withdrawal syndrome: a clinical and electroencephalographic study. Electroencephalogr Clin Neurophysiol Suppl 1959;14.
26
Essig CF . Clinical and experimental aspects of barbiturate withdrawal convulsions. Epilepsia 1967;8:21-30
CrossRef | Medline27
Marciani MG ,Gotman J ,Andermann F ,Olivier A . Patterns of seizure activation after withdrawal of antiepileptic medication. Neurology 1985;35:1537-1543
Web of Science | Medline28
Gotman J ,Marciani MG ,Gloor P ,Quesney LF ,Sherwin A . Effects of withdrawal of anticonvulsant medication on ictal and interictal EEG activity. Clin Neuropharmacol 1984;7:Suppl 1:132-133 abstract.
CrossRef29
Bromfield EB ,Dambrosia J ,Devinsky O ,Nice FJ ,Theodore WH . Phenytoin withdrawal and seizure frequency. Neurology 1989;39:905-909
Web of Science | Medline30
Rodin EA, John G. Withdrawal of anticonvulsant medications in successfully treated patients with epilepsy. In: Wada JA, Penry JK, eds. Advances in epileptology: the Xth Epilepsy International Symposium. New York: Raven Press, 1980:183-6.
31
Todt H . The late prognosis of epilepsy in childhood: results of a prospective follow-up study. Epilepsia 1984;25:137-144
CrossRef | Web of Science | Medline32
Annegers JF ,Hauser WA ,Elveback ER . Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:729-737
CrossRef | Web of Science | Medline33
Thurston JH ,Thurston DL ,Hixon BB ,Keller AJ . Prognosis in childhood epilepsy: additional follow-up of 148 children 15 to 23 years after withdrawal of anticonvulsant therapy. N Engl J Med 1982;306:831-836
Full Text | Web of Science | Medline34
Janz D, Sommer-Burkhardt E-M. Discontinuation of antiepileptic drugs in patients with epilepsy who have been seizure-free for more than two years. In: Janz D, ed. Epileptology: proceedings of the Seventh International Symposium on Epilepsy, Berlin (West), June 1975. Stuttgart, Germany: Georg Thieme Verlag, 1976:228-34.
35
Pestre M ,Loiseau P ,Dartigues JF ,Larrieu E ,Cohadon S . Arret du traitement dans les crises epileptiques de l'adolescence. Rev Neurol (Paris) 1987;143:40-46
Web of Science | Medline
- Citing Articles (30)
Citing Articles
1
John D. Hixson. (2010) Stopping Antiepileptic Drugs: When and Why?. Current Treatment Options in Neurology 12:5, 434-442
CrossRef2
Jeffrey W. Britton. (2010) Significance of the EEG and Epileptiform Abnormalities in Antiepileptic Drug Discontinuance. Journal of Clinical Neurophysiology 27:4, 249-254
CrossRef3
Sebahattin Vurucu, Mehmet Saldir, Bulent Unay, Ridvan Akin. (2010) Determination of risk factors associated with seizure relapse after antiepileptic drug withdrawal. Central European Journal of Medicine 5:2, 251-256
CrossRef4
J. Ramos-Lizana, J. Aguirre-Rodríguez, P. Aguilera-López, E. Cassinello-García. (2010) Recurrence risk after withdrawal of antiepileptic drugs in children with epilepsy: A prospective study. European Journal of Paediatric Neurology 14:2, 116-124
CrossRef5
Dieter Schmidt. (2009) Drug treatment of epilepsy: Options and limitations. Epilepsy & Behavior 15:1, 56-65
CrossRef6
Jerry J. Shih, Juan G. Ochoa. (2009) A Systematic Review of Antiepileptic Drug Initiation and Withdrawal. The Neurologist 15:3, 122-131
CrossRef7
Willem F.M. Arts, Ada T. Geerts. (2009) When to start drug treatment for childhood epilepsy: The clinical–epidemiological evidence. European Journal of Paediatric Neurology 13:2, 93-101
CrossRef8
Nevzat Gueler, Günter Krämer. (2009) Behandlungsstrategien mit Antiepileptika, Ein- und Ausschleichen. Zeitschrift für Epileptologie 22:1, 13-19
CrossRef9
Matthias J. Koepp, Fiona Farrell, Jayne Collins, Shelagh Smith. (2008) The prognostic value of long-term ambulatory electroencephalography in antiepileptic drug reduction in adults with learning disability and epilepsy in long-term remission. Epilepsy & Behavior 13:3, 474-477
CrossRef10
Bernhard Schmitt, Michael Albani, Thomas Bast, Ulrich Brandl, Rudolf Korinthenberg, Gerhard Kurlemann, Bernd Neubauer, Ulrich Stephani, Markus Wolff, . (2007) Epilepsie im Kindesalter: Wann kann die antiepileptische Therapie abgesetzt werden?. Zeitschrift für Epileptologie 20:3, 113-119
CrossRef11
Celina C. Martinez, Paula L. Pyzik, Eric H. Kossoff. (2007) Discontinuing the Ketogenic Diet in Seizure-Free Children: Recurrence and Risk Factors. Epilepsia 48:1,
CrossRef12
Lakshmi Narasimhan Ranganathan, Sridharan Ramaratnam, Lakshmi Narasimhan Ranganathan. 2006. Rapid versus slow withdrawal of antiepileptic drugs. .
CrossRef13
Raja B. Khan, Arzu Onar. (2006) Seizure Recurrence and Risk Factors after Antiepilepsy Drug Withdrawal in Children with Brain Tumors. Epilepsia 47:2, 375-379
CrossRef14
Anne T. Berg, Barbara G. Vickrey, John T. Langfitt, Michael R. Sperling, Shlomo Shinnar, Carl Bazil, Thaddeus Walczak, Susan S. Spencer, . (2006) Reduction of AEDs in Postsurgical Patients Who Attain Remission. Epilepsia 47:1, 64-71
CrossRef15
LN Ranganathan, S Ramaratnam, Lakshmi Narasimhan Ranganathan. 2004. Rapid versus slow withdrawal of antiepileptic drugs. .
CrossRef16
Anne T. Berg. (2004) Postsurgical Treatment of Epilepsy. Epilepsy Currents 4:4, 127-130
CrossRef17
Luigi M Specchio, Ettore Beghi. (2004) Should Antiepileptic Drugs Be Withdrawn in Seizure-Free Patients?. CNS Drugs 18:4, 201-212
CrossRef18
J. W. Britton. (2002) Antiepileptic Drug Withdrawal: Literature Review. Mayo Clinic Proceedings 77:12, 1378-1388
CrossRef19
O Snead. (2001) Surgical treatment of medically refractory epilepsy in childhood. Brain and Development 23:4, 199-207
CrossRef20
Christine O'Dell, Shlomo Shinnar. (2001) Initiation and discontinuation of antiepileptic drugs. Neurologic Clinics 19:2, 289-311
CrossRef21
Adrian J. Fowle, Colin D. Binnie. (2000) Uses and Abuses of the EEG in Epilepsy. Epilepsia 41:s3, S10-S18
CrossRef22
Sakir Altunbasak, Ömer Artar, Refik Burgut, Dinçer Yildiztas. (1999) Relapse risk analysis after drug withdrawal in epileptic children with uncomplicated seizures. Seizure 8:7, 384-389
CrossRef23
Alberto Verrotti, Simonetta Morresi MD, Rocco Cutarella, Guido Morgese, Francesco Chiarelli. (1999) ‘Factors associated with relapse after antiepileptic drug withdrawal in a selected population with partial epilepsy’. Developmental Medicine & Child Neurology 41:9, 643-645
CrossRef24
Benigno E. Caviedes, Jose L. Herranz. (1998) Seizure recurrence and risk factors after withdrawal of chronic antiepileptic therapy in children. Seizure 7:2, 107-114
CrossRef25
Gunnar Braathen, Hans Melander. (1997) Early Discontinuation of Treatment in Children with Uncomplicated Epilepsy: A Prospective Study with a Model for Prediction of Outcome. Epilepsia 38:5, 561-569
CrossRef26
Kevin Gordon, Judith MacSween, Joseph Dooley, Carol Camfield, Peter Camfield, Bruce Smith. (1996) Families Are Content to Discontinue Antiepileptic Drugs at Different Risks Than Their Physicians. Epilepsia 37:6, 557-562
CrossRef27
Albert D. Fraser. (1996) New drugs for the treatment of epilepsy. Clinical Biochemistry 29:2, 97-110
CrossRef28
A. Matricardi, F. Bertamino, D. Risso. (1995) Discontinuation of anti-epileptic therapy: A retrospective study of 86 children and adolescents. The Italian Journal of Neurological Sciences 16:8, 613-622
CrossRef29
Filippo Donati, Ralph I. Hassink, Hans Jung, Franco Vassella. (1995) Factors predicting the risk of relapse after antiepileptic drug discontinuation in children with partial seizures. European Journal of Pediatrics 154:S4, S44-S47
CrossRef30
Richard E Appleton. (1995) Treatment of childhood epilepsy. Pharmacology & Therapeutics 67:3, 419-431
CrossRef
